CompletedPhase 3NCT00104520
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Karen McCoy, MDNationwide Children's Hospital
- Intervention
- AZLI 75 mg two times a day (BID)/three times a day (TID)(drug)
- Enrollment
- 211 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2005 – 2006
Study locations (30)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- University of California, San Diego, La Jolla, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Kaiser Permanente Medical Care Program, Oakland, California, United States
- Children's Hospital, Orange Co., Orange, California, United States
- Stanford University Hospital and Medical Center, Palo Alto, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- Children's Hospital, Denver, Colorado, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- University of Florida Health Sciences Center, Gainesville, Florida, United States
- Nemours Children's Clinic, Jacksonville, Jacksonville, Florida, United States
- University of Miami School of Medicine, Miami, Florida, United States
- Nemours Children's Clinic, Orlando, Florida, United States
- Pediatric Pulmonary Associates, Florida, St. Petersburg, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00104520 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.